Final-Program-ATS-2023-AP.vp

WEDNESDAY • MAY 24

305

9:20 Wrap up - Q & A with All Faculty and Audience K.K. Brown, MD, Denver, CO This session and the International Conference are supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL CLINICAL TOPICS IN PULMONARY MEDICINE CME Credits Available: 1.5 COUGH IN PULMONARY FIBROSIS - ANNOYING SYMPTOM OR DRIVER/MARKER OF DISEASE PROGRESSION?

D2

CLINICAL • TRANSLATIONAL CLINICAL TOPICS IN PULMONARY MEDICINE CME Credits Available: 1.5

Assembly on Clinical Problems 8:00 AM - 9:30 AM Walter E. Washington Convention Center Room 207 A-B (Level 2) Target Audience Healthcare providers that care for patients with fibrotic lung diseases, researchers studying cough in patients with pulmonary fibrosis, patients with pulmonary fibrosis and caregivers of patients with pulmonary fibrosis. Objectives At the conclusion of this session, the participant will be able to: • describe the mechanisms of cough and treat cough in patients with pulmonary fibrosis • to refer patients with pulmonary fibrosis to ongoing clinical trials • measure cough in a standardized manner This session will focus on the pathobiology, approach to treatment, the role of cough as a potential biomarker of disease activity/progression and current landscape of recent on ongoing research on cough in patients with pulmonary fibrosis. Chairing: K.R. Flaherty, MD, Ann Arbor, MI L.H. Lancaster, MD, Nashville, TN K.K. Brown, MD, Denver, CO 8:00 Understanding the Pathobiology of Cough in Patients with Pulmonary Fibrosis S.S. Birring, MD, London SE5 9RS, United Kingdom 8:20 Approach to Patient with Pulmonary Fibrosis and Cough, What Can We Learn from the Chronic Cough Field? M. Wijsenbeek, MD, PhD, Rotterdam, Netherlands 8:40 Cough as a Prognostic Biomarker, Should We Be Formally Measuring in Clinical Practice? T.M. Maher, MD, MSc, PhD, FRCP, Los Angeles, CA 9:00 Cough in Pulmonary Fibrosis Clinical Trials: Nothing to Sneeze At S.D. Nathan, MD, Falls Church, VA

D3 IMAGING BIOMARKERS OF DISEASE MODIFICATION IN COPD Assemblies on Clinical Problems; Respiratory Structure and Function 8:00 AM - 9:30 AM Walter E. Washington Convention Center Ballroom C (Level 3) Target Audience Providers of lung health, clinical researchers, those designing and/or conducting clinical trials, those designing and evaluating therapies for COPD, industry executives, government and granting administrators Objectives At the conclusion of this session, the participant will be able to: • define new applications of quantitative imaging for the management of COPD in clinical practice • apply quantitative imaging approaches to guide pharmacotherapy and lung volume reduction for individuals with COPD • incorporate quantitative CT in shared decision making for COPD management with patients and families Disease progression and outcomes in COPD have been classically measured by assessing lung function and clinical symptoms. Advanced quantitative imaging is increasingly used to quantify the features of COPD, specifically emphysema, air trapping, and airway abnormality. Attendees of this session will understand how imaging biomarkers are currently related to disease modification framework in COPD related to prevention and treatments, such as: early diagnosis, inhaled therapies, surgical and bronchoscopic interventions, and pulmonary rehabilitation. Furthermore, this session will discuss the advanced methodologies for functional lung imaging in contrast and combination with physiological assessment of disease biomarkers. Chairing: S.P. Bhatt, MD, MSPH, Birmingham, AL T. Siddharthan, MD, Miami, FL 8:00 Ventilation Heterogeneity in COPD Patients T. Siddharthan, MD, Miami, FL

ATS 2023 • Washington, DC